Through this platform, resistance in bacterial samples can be tested within two hours compared to 24-27 hours through other ...

The crucial drugs can have unintended consequences. Innovative therapies could shield the microbiome from their effects.

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

An expert briefly describes the study ‘Single Dose Aminoglycosides versus Carbapenems for the Treatment of Uncomplicated ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

Traditional diagnostic methods, such as bacterial culture and PCR-based testing, can take 24–72 hours, delaying critical ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

Antimicrobial resistance (AMR) is a critical global health challenge, requiring early and accurate detection of resistance ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

Addresses the significant threat of antimicrobial resistance.